Tumor-infiltrating Tregs (TITR) constitute a sub-family of immuno-suppressive cells abundantly found in multiple solid cancers. They play a critical role in tumor progression and their specific depletion has been recently propose as a novel therapeutic strategy to fight cancers. Based on the transcriptional analysis of tumor infiltrating immune cells, the G-protein coupled receptor CCR8 was found to be expressed on murine and human TITR, but not on proinflammatory effector T cells. The CCR8 receptor therefore represents a unique TITR target for the development of novel depletive antibody-based therapeutics. At Domain Therapeutics, a diverse library of several dozens of mouse mAbs directed against the hCCR8 was discovered and characterized, providing a unique source for the development of a best-in-class and well differentiated anti-hCCR8 depleting antibody for the treatment of cancers.Special attention was paid on two important characteristics for the selection of our depleting mAb candidates: (1) their ability to detect all CCR8 positive immunosuppressive cells and (2) the combination of different killing modes of action (ADCC, ADCP, CDC) to trigger an optimal depletion.Our selected mAb candidates were nominated based on their capacity to bind to immunosuppressive cells present in different tumor tissues and optimal depleting activity. The impact of our mAbs on tumor growth and on the immune tumor microenvironment (TME) were also studied in mouse hCCR8-KI mice. Finally, following a comprehensive in vitro benchmarking mAb analysis, we identified key differentiating points versus competitor’s mAbs. Nominated candidates wil be ready to enter cell line generation efforts in early 2023. Citation Format: Iseulys Richert, Malaury Schappler, Alice Gentil Dit Maurin, Megane Jeannelle, Solene Rose, Pauline Urquia, Dounia Chraa, Luc Baron, Maria Dolores Garcia Fernandez, Quentin Ruet, Camille Dietsch, Orphee Blanchard, Safia Ayachi, Christel Franchet, Alexandre Fontayne, Claudine Vermot-Desroches, Stephan Schann, Nathalie Lenne. Depleting hCCR8 mAb Therapy #2: Selection of candidates for the development of innovative depleting anti CCR8 therapeutic antibodies to control the immunosuppressive tumor microenvironment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2945.
Background: Tumor-infiltrating Tregs (TITR) constitute a sub-family of immuno-suppressive cells abundantly found in multiple solid cancers. They play a critical role in tumor progression and their specific depletion has been recently proposed as a novel therapeutic strategy to fight cancers. Based on the transcriptional analysis of tumor infiltrating immune cells, the G-protein coupled receptor CCR8 was found to be expressed on murine and human TITR, but not on proinflammatory effector T cells. The CCR8 receptor therefore represents a unique TITR target for the development of novel depletive antibody-based therapeutics. Methods: We have generated a broad collection of monoclonal antibodies (mAb) directed against the human CCR8 receptor. This collection was widely characterized using different sources of recombinant and native hCCR8 positive cell subsets. Moreover, their binding and activities in several functional assays were assessed with different approaches (BRET, Flow Cytometry, including the inhibition of recruitment of different G-proteins to the CCR8 receptor). A comprehensive molecular and pharmacological characterization of each mAb of our proprietary library was generated. mAb binding against different peptides mimicking different states of post-translational modifications of the N-terminus of CCR8 was also monitored. Finally, using two surrogate antibodies directed against the mouse receptor, we tested the role of CCR8 antagonism and Treg depletion in multiple syngeneic models. Results: A comprehensive characterization of Domain Therapeutics’ mAb library revealed distinct mAb cellular reactivity profiles, different epitope recognition patterns (based on binding to different peptides with different post-translational modifications), subnanomolar antagonist activity of downstream signaling, and insurmountable property with regards to the CCR8 ligand CCL1. Moreover, we demonstrated that treatment with a depleting anti-mCCR8 mAb translated into robust anti-tumor activity in multiple syngeneic mouse models. Conclusion: Due to its high and relatively specific expression on tumor-infiltrating Tregs, CCR8 represents an attractive novel target to derive novel immunotherapies. At Domain Therapeutics, a mAb library of several dozen antibodies with distinct and differentiated binding and pharmacological activity profile was successfully discovered and patent-protected. This collection constitutes a unique source of future clinical candidates for the development of a best-in-class well-differentiated anti-hCCR8 depleting antibody for the treatment of cancers. Citation Format: Claudine Vermot-Desroches, Iseulys Richert, Malaury Schappler, Alice Gentil Dit Maurin, Megane Jeannelle, Solene Rose, Luc Baron, Quentin Ruet, Camille Dietsch, Pauline Urquia, Safia Ayachi, Orphee Blanchard, Maria Dolores Garcia Fernandez, Christel Franchet, Nathalie Lenne, Stephan Schann. Depleting hCCR8 mAb Therapy #1: Characterization of a broad collection of anti-hCCR8 mAbs [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2946.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.